2. Signaling Pathways
  3. Others
  4. Others
  5. Others Antagonist

Others Antagonist

Others Antagonists (54):

Cat. No. Product Name Effect Purity
  • HY-111444
    Auxinole
    		Antagonist 99.89%
    Auxinole is a potent auxin antagonist of TIR1/AFB receptors, binding TIR1 to block the formation of the TIR1-IAA-Aux/IAA complex and so inhibits auxin-responsive gene expression.
  • HY-P99168
    Anifrolumab
    		Antagonist 99.48%
    Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research.
  • HY-129241
    AGX51
    		Antagonist 99.09%
    AGX51 is a first-in-class pan-Id (inhibitors of DNA-binding/differentiation proteins) antagonist and degrader. AGX51 inhibits the Id1-E47 interaction, leading to ubiquitin-mediated degradation of Ids, cell growth arrest, and reduces viability. AGX51 inhibits the TNBC cell lines with IC50s of nearly 25 μM. AGX51 can be used for the research of cancer.
  • HY-P3212
    Allo-aca
    		Antagonist 99.71%
    Allo-aca, a leptin peptidomimetic, is a potent, specific leptin receptor antagonist peptide. Allo-aca blocks leptin signaling and action in numerous in vitro and in vivo models.
  • HY-112730
    PEO-IAA
    		Antagonist 99.11%
    PEO-IAA is an indole-3-acetic acid (IAA) antagonist. PEO-IAA is an auxin antagonist that binds to transport inhibitor response 1/auxin signaling F-box proteins (TIR1/AFBs).
  • HY-B0079
    Sugammadex sodium
    		Antagonist ≥98.0%
    Sugammadex sodium is a synthetic γ-cyclodextrin derivative, and acts as a reversal agent for neuromuscular block. Sugammadex sodium shows nephroprotective effect in ischemia-reperfusion injury.
  • HY-101483
    Dihydromunduletone
    		Antagonist 99.96%
    Dihydromunduletone (DHM) is a rotenoid derivative and a selective, potent adhesion G protein-coupled receptor (aGPCR) (GPR56 and GPR114/ADGRG5) antagonist with an IC 50 of 20.9 μM for GPR56, but not inhibit GPR110 or class A GPCRs.
  • HY-12664
    AF64394
    		Antagonist 98.01%
    AF64394 is a GPR3 inverse agonist, with a pIC50 of 7.3.
  • HY-P0257
    Astressin
    		Antagonist 99.52%
    Astressin is a potent corticotropin releasing factor (CRF) antagonist.
  • HY-P1023
    VIP(6-28)(human, rat, porcine, bovine)
    		Antagonist 98.85%
    VIP(6-28)(human, rat, porcine, bovine) is an effective antagonist of the actions of exogenous vasoactive intestinal peptide (VIP) on cAMP.
  • HY-P1242
    NEP(1-40)
    		Antagonist 98.83%
    NEP(1-40) is a Nogo-66 receptor (NgR) antagonist peptide, reversing the injury-induced shift in distribution of microglia morphologies by limiting myelin-based inhibition.
  • HY-150205
    Succinate/succinate receptor antagonist 1
    		Antagonist 99.46%
    Succinate/succinate receptor antagonist 1 (compound 7a) is a succinate/succinate receptor antagonist. Succinate/succinate receptor antagonist 1 blocks succinate signaling in gingival tissue. Succinate/succinate receptor antagonist 1 inhibits the activation of succinate receptor 1 (SucnRl) with an IC50 value of 20 μΜ. Succinate/succinate receptor antagonist 1 can be used for the research of periodontal disease.
  • HY-157189
    GPR132 antagonist 1
    		Antagonist 99.43%
    GPR132 antagonist 1 (GPR132-B-160, Compound 25) is a GPR132 antagonist with an EC50 value of 0.075 μM. GPR132 antagonist 1 has promote insulin secretion activity with an EC50 value of 0.7 μM.
  • HY-B1014
    Acenocoumarol
    		Antagonist 99.87%
    Acenocoumarol is an anticoagulant that functions as a Vitamin K antagonist.
  • HY-P2026
    A 71915
    		Antagonist 99.29%
    A 71915 is a highly potent and competitive natriuretic peptide receptor A (ANP, NPRA) antagonist (pKi= 9.18). A 71915 displaces [125I]ANP dose dependently, with a Ki of 0.65 nM. A71915( pA2= 9.48) against rat ANP-induced cGMP production in NB-OK-1 cells.
  • HY-P1419
    AP 811
    		Antagonist
    AP 811 is a selective atrial natriuretic peptide clearance receptor (ANP-CR, NPR3) antagonist with a Ki of 0.48 nM. AP 811 displays >20000-fold selectivity for NPR3 over NPR1. AP 811 abolishes ANP-induced pump stimulation.
  • HY-101527
    20-HEDE
    		Antagonist ≥98.0%
    20-HEDE (WIT 002) is an antagonist of 20-hydroxyeicosatetraenoic acid (20-HETE).
  • HY-B0325
    Phenindione
    		Antagonist 99.22%
    Phenindione is an anticoagulant which functions as a Vitamin K antagonist.
  • HY-14854
    Tecarfarin
    		Antagonist 98.65%
    Tecarfarin (ATI-5923) is an orally active and non-competitive vitamin K epoxide reductase (VKOR) antagonist, and impairs the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Tecarfarin has the antithrombotic activity .
  • HY-108624
    CYM 50769
    		Antagonist 98.68%
    CYM 50769 is a non-peptidic selective antagonist of neuropeptides B and W receptor 1 (NPBWR1). CYM 50769 can attenuates the NPW-23-induced cell proliferation in ATDC5. CYM 50769 can be used for researching endochondral bone formation.